Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-491CLD versus olmesartan medoxomil + hydrochlorothiazide in hypertension with moderate renal impairment
NL-OMON36082Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azilsartan medoxomil, chlorthalidone, olmesartan and hydrochlorothiazide in hypertension (HTN) (2 arms), sponsored by Takeda. Primary endpoint: Subjects with at least 1 adverse event. Planned start Apr 2011; status: not yet recruiting.
02
Drugs
azilsartan medoxomilchlorthalidoneolmesartanhydrochlorothiazide
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NL-OMON36082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36082.